AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 91 min read$CNXC

Caldwell Christopher A purchased $21K of CNXC

Caldwell Christopher A (President and CEO) purchased 1,000 shares of Concentrix Corp (CNXC) at $21.25 on 2026-07-08.

Original reporting
SEC EDGAR · Caldwell Christopher A
Published Jul 9, 2026, 10:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 9, 2026, 10:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CNXC
Bullish
medium confidence
Mentioned
$CNXC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CNXCBullishLow
01

Why it matters

Traders may treat the CEO purchase as a modest positive sentiment input, but it does not provide new operational, financial, or regulatory information.

02

Market read

A primary-source insider buy is newly disclosed, but the transaction size suggests limited impact on valuation or near-term trading flows.

03

What to watch

No 10b5-1 plan is disclosed, but the filing does not provide intent, timing constraints, or whether the purchase is part of a broader pattern.

Relevance 4/10Novelty 5/10Timing: Form 4 filed 2026-07-09, covering a 2026-07-08 insider purchase.

Background

The article is a SEC Form 4 insider transaction disclosure for Concentrix (CNXC) by its President and CEO.

Company-level read

Ticker impact

$CNXCBullishMedium confidence
Context

Concentrix CEO bought 1,000 shares on 2026-07-08 at $21.2497, per Form 4 filed 2026-07-09, with no 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by additional disclosures.

Evidence & confidence

Form 4 provides a primary-source transaction, but the disclosed size ($21.25k) is small relative to company scale and the filing includes no 10b5-1 plan, which may increase interpretive attention without changing fundamentals.

Market effects

Sector

Minimal; insider purchase does not materially change the broader IT services/outsourcing read-through.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider open-market buys can be routine liquidity or diversification-related, and the small dollar amount reduces signal strength.

Key entities

  • issuer
    Concentrix Corp

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Caldwell Christopher A

    President and CEO who purchased 1,000 shares open-market at $21.2497 on 2026-07-08.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CNXC insider trading history →

Related articles

SEP 30
$CNXCHighAI 8/10

Concentrix earnings analysis: questions answered and next catalysts

Concentrix Corp (CNXC) reported Q3 earnings with a $0.21 EPS beat ($2.92) but a $30M revenue miss ($2.45B vs. $2.48B est). Shares initially dropped 9.77% before recovering 3.12%. Management highlighted AI-driven revenue growth (50% of total) and cash flow strength ($218M), but revenue declines due to specific client exits and offshoring. The dividend was raised to $0.37/share. Growth is expected to return in 2028, with key catalysts including Q4 earnings and debt paydown milestones.

investing.com2 min
SEP 30
$CNXCMedAI 8/10

Why Concentrix Stock Ended Up Moving Higher Today

Concentrix (CNXC) reported fiscal Q3 revenue below estimates due to client shifts, but earnings beat expectations. CEO Christopher Caldwell attributed the shortfall to client preferences, not customer loss. The stock initially dropped but recovered, up 3% by midday. Analysts' average price target is $33.50, over 30% above current levels.

aol.com3 min
SEP 30
$LQDAMed

Stocks making the biggest moves midday: Rogers, United Therapeutics, Moderna, FormFactor & more

Rogers rose 10% on higher earnings guidance ($3.80 vs. $3.65 consensus). Liquidia fell 25% after a patent infringement ruling, while United Therapeutics gained 15%. Jabil dropped 7% despite beating earnings and revenue estimates. Concentrix climbed 5% on strong earnings but issued weak guidance. Moderna fell 7% after a Citi downgrade. FormFactor gained 8% on a Deutsche Bank buy rating. Cal-Maine Foods declined 2% on a wider-than-expected loss.

cnbc.com2 min
SEP 30
$CNXCLow

Why Concentrix (CNXC) Stock Is Up Today

Concentrix (CNXC) stock rose 4% after reporting a Q3 net loss of $988.1M, driven by a $1.5B goodwill impairment charge. Revenue fell 1.2% YoY to $2.45B, missing estimates. Adjusted EPS was $2.92. The company cited AI deployments and client decisions for the decline. Shares later cooled to $25.73, up 1%.

stockstory.org2 min